Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neurology

Safety First: Risk Mitigation and Monitoring

At a Glance

High-efficacy treatments for relapsing-remitting multiple sclerosis can reduce relapses but require planned screening and monitoring. Blood tests, MRI scans, vaccine timing, and attention to infection or neurological warning signs help manage treatment risks.

While high-efficacy Disease-Modifying Therapies (DMTs) offer powerful protection against MS relapses, they do so by significantly altering how your immune system functions. This shift requires a proactive safety strategy. You and your care team will use a combination of blood tests, MRIs, and clinical monitoring to identify important risks and establish a plan to reduce and monitor them [1][2].

The Pre-Treatment Checklist

Before you receive your first dose of a high-efficacy DMT, your doctor will perform a “baseline” screening. This ensures your body is ready for treatment and that there are no silent infections that could become active once you are immunosuppressed [3].

  • Hepatitis B & TB Screening: You may be tested for Hepatitis B (HBV) and latent Tuberculosis (TB). Anti-CD20 therapies, in particular, can cause a dormant HBV infection to reactivate [4][5].
  • Vaccination Status: Because these drugs can make vaccines less effective, coordinate closely with your prescriber. Live vaccines (like the varicella/chickenpox vaccine) often require significant lead time and cannot be given during treatment. Non-live vaccines (like flu, COVID-19, and pneumonia shots) can usually still be given, but they may need specific timing relative to your doses to be fully effective [6][7].
  • Varicella (Chickenpox/Shingles): If you do not have antibodies to the varicella-zoster virus, you may need a vaccine series before starting certain treatments like S1P modulators [8].

Monitoring Specific Medications

Each DMT has its own “safety signature” that dictates how you will be monitored. Never change or stop your medication based on a lab result without consulting your prescriber.

Natalizumab and the PML Risk

The most significant concern with natalizumab is PML (Progressive Multifocal Leukoencephalopathy), a rare but serious brain infection caused by the JC virus (JCV) [9].

  • The JCV Index: If you take this medication, you will have your blood tested for JCV antibodies. The “index” value helps categorize your risk: ranges span from negative to indeterminate, intermediate, or higher risk. A negative test makes the risk much lower but does not make it zero. The risk also depends on how long you have been on the drug and prior use of immunosuppressants [10][11].
  • Surveillance MRIs: Depending on your JCV status, your doctor may order MRIs more frequently (e.g., every 3 to 6 months for those at higher risk) to look for presymptomatic signs of PML [1][12].

Anti-CD20 Therapies (Ocrelizumab, Ofatumumab)

These treatments target B-cells, which are vital for fighting infections.

  • Hypogammaglobulinemia: Over time, these drugs can lower your levels of immunoglobulins (IgG), the proteins your body uses to “remember” and fight germs [2]. Your doctor should monitor these levels via blood work; if they drop too low, you may be at a higher risk for persistent respiratory or urinary tract infections [13].
  • Neutropenia: Rarely, these drugs can cause a drop in “neutrophils,” a different type of white blood cell. Periodic complete blood counts (CBC) are standard [14].

S1P Modulators and Fumarates

These oral medications require monitoring of your internal organs and basic blood counts.

  • Cardiac and Liver Health: Certain S1P modulators can initially slow your heart rate. Depending on the drug and your profile, they may require a 6-hour observation period for the first dose [15][16]. They also require regular liver enzyme tests (ALT/AST) and blood pressure checks [17][18].
  • Lymphopenia: Both S1P modulators and dimethyl fumarate lower your Absolute Lymphocyte Count (ALC). If your ALC drops significantly, your doctor will track it carefully to prevent opportunistic infections [19][20].
  • Macular Edema: Some S1P modulators can cause fluid buildup in the back of the eye, requiring an eye exam 3 to 4 months after starting the drug depending on individual risk [21].

When to Call Your Doctor vs Emergency Services

Safety monitoring is a partnership. While your medical team watches your lab results, you must watch for physical “red flags.”

  1. Neurological Changes (Urgent): New or worsening confusion, memory loss, balance issues, or vision changes (which could signal PML) [9][22].
  2. Infection Signs (Prompt Clinic Call): A fever that won’t go away, a persistent productive cough, or pain during urination. Keep in mind that immunosuppressed patients might not always develop a high fever [13].
  3. Liver Symptoms (Prompt Clinic Call): Yellowing of the skin or eyes (jaundice), dark-colored urine, or severe pain in the upper right side of your abdomen [23].
  4. Rebound Effect (Urgent): If you stop taking a medication like fingolimod, be alert for a sudden, severe “rebound” of MS symptoms 2 to 4 months after your last dose. Always transition medications under a doctor’s supervision [24].

Common questions in this guide

What screening is needed before starting a high-efficacy MS treatment?
Before some high-efficacy disease-modifying therapies, clinicians may screen for hepatitis B and tuberculosis and review vaccination and varicella immunity. Vaccines, especially live vaccines, may need to be completed or timed before treatment begins.
What does a JCV antibody result mean for natalizumab treatment?
The JCV antibody index helps estimate the risk of PML, a rare brain infection, in people taking natalizumab. A negative result lowers risk but does not eliminate it; risk also depends on treatment duration and previous immunosuppressant use. The care team may use regular MRI scans to look for early signs.
What should be monitored with ocrelizumab or ofatumumab?
These anti-CD20 medicines can lower immunoglobulin G, or IgG, proteins that help fight infections, and rarely reduce neutrophils, a type of white blood cell. Blood tests can track immunoglobulin levels and complete blood counts, while persistent respiratory or urinary infections should be reported.
What monitoring do S1P modulators and dimethyl fumarate require?
Depending on the medicine and your health history, S1P modulators may require first-dose heart-rate observation, liver enzyme and blood-pressure checks, and an eye exam for macular edema. S1P modulators and dimethyl fumarate can lower lymphocyte counts, so regular blood counts help guide monitoring.
Which symptoms should prompt a call while taking an MS DMT?
Seek urgent medical advice for new confusion, memory problems, balance trouble, or vision changes, especially while taking natalizumab. Contact the treating clinic promptly for persistent fever, cough, painful urination, jaundice, dark urine, or severe upper-right abdominal pain, even if fever is mild or absent.
Is it safe to stop fingolimod without a plan?
Do not stop fingolimod or change another DMT based on a lab result without contacting the prescriber. Stopping fingolimod can be followed by a severe rebound of MS symptoms two to four months later, so any switch should be supervised.

Get notified when new evidence is published on relapsing-remitting multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

    McGuigan C, Craner M, Guadagno J, et al.

    Journal of neurology, neurosurgery, and psychiatry 2016; (87(2)):117-25 doi:10.1136/jnnp-2015-311100.

    PMID: 26492930
  2. 2

    Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

    Athni TS, Barmettler S

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):699-712 doi:10.1016/j.anai.2023.01.018.

    PMID: 36706910
  3. 3

    Evaluating the risk: Hepatitis B virus reactivation in ocrelizumab-treated patients with multiple sclerosis: A single-center experience and review of the literature.

    Ozbay BO, Kulu U, Baştuğ A, et al.

    Multiple sclerosis and related disorders 2026; (113()):107371 doi:10.1016/j.msard.2026.107371.

    PMID: 42431141
  4. 4

    Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis.

    Ciardi MR, Iannetta M, Zingaropoli MA, et al.

    Open forum infectious diseases 2019; (6(1)):ofy356 doi:10.1093/ofid/ofy356.

    PMID: 30697576
  5. 5

    Ocrelizumab-induced organizing pneumonia in multiple sclerosis: case report and literature review.

    Usman S, Cheema M, Ghuman Z, et al.

    Archive of clinical cases 2024; (11(2)):69-73 doi:10.22551/2024.43.1102.10291.

    PMID: 39015300
  6. 6

    Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.

    Novak F, Nilsson AC, Nielsen C, et al.

    Multiple sclerosis and related disorders 2021; (56()):103251 doi:10.1016/j.msard.2021.103251.

    PMID: 34571415
  7. 7

    Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.

    van Kempen ZLE, Hogenboom L, Toorop AA, et al.

    Annals of neurology 2023; (93(1)):103-108 doi:10.1002/ana.26534.

    PMID: 36250739
  8. 8

    A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients.

    Sharma K, Chaudhary D, Beard K, et al.

    Multiple sclerosis and related disorders 2022; (59()):103675 doi:10.1016/j.msard.2022.103675.

    PMID: 35168095
  9. 9

    Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

    Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, et al.

    JAMA neurology 2018; (75(7)):827-833 doi:10.1001/jamaneurol.2018.0094.

    PMID: 29532061
  10. 10

    Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.

    Ho PR, Koendgen H, Campbell N, et al.

    The Lancet. Neurology 2017; (16(11)):925-933 doi:10.1016/S1474-4422(17)30282-X.

    PMID: 28969984
  11. 11

    Natalizumab-associated progressive multifocal leukoencephalopathy.

    Glenn T, Berger JR, McEntire CRS

    Frontiers in neurology 2025; (16()):1575653 doi:10.3389/fneur.2025.1575653.

    PMID: 40621097
  12. 12

    Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.

    Major EO, Yousry TA, Clifford DB

    The Lancet. Neurology 2018; (17(5)):467-480 doi:10.1016/S1474-4422(18)30040-1.

    PMID: 29656742
  13. 13

    Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD.

    Mears V, Jakubecz C, Seeco C, et al.

    Journal of neuroimmunology 2023; (377()):578066 doi:10.1016/j.jneuroim.2023.578066.

    PMID: 36917920
  14. 14

    Neutropaenia complications from Ocrelizumab and Rituximab treatment.

    Pang V, Seery N, Wesselingh R, et al.

    Multiple sclerosis and related disorders 2024; (81()):105147 doi:10.1016/j.msard.2023.105147.

    PMID: 38043368
  15. 15

    Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.

    Ordoñez-Boschetti L, Rey R, Cruz A, et al.

    Advances in therapy 2015; (32(7)):626-35 doi:10.1007/s12325-015-0224-2.

    PMID: 26170105
  16. 16

    Cardiac arrhythmias associated with S1PRMs: a pharmacovigilance study based on real-world data.

    Wang S, Xie L, Ma P

    Frontiers in pharmacology 2026; (17()):1882323 doi:10.3389/fphar.2026.1882323.

    PMID: 42682484
  17. 17

    Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study.

    Maniscalco GT, Sparaco M, Di Gregorio M, et al.

    Journal of neurology 2025; (272(9)):559 doi:10.1007/s00415-025-13300-z.

    PMID: 40770143
  18. 18

    Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.

    Lassiter G, Melancon C, Rooney T, et al.

    Neurology international 2020; (12(3)):89-108 doi:10.3390/neurolint12030016.

    PMID: 33287177
  19. 19

    Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations.

    Fox RJ, Chan A, Gold R, et al.

    Neurology. Clinical practice 2016; (6(3)):220-229 doi:10.1212/CPJ.0000000000000238.

    PMID: 27347439
  20. 20

    Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.

    Wood CH, Robertson NP, Htet ZM, Tallantyre EC

    Multiple sclerosis and related disorders 2022; (58()):103492 doi:10.1016/j.msard.2022.103492.

    PMID: 35066268
  21. 21

    Siponimod-associated cystoid macular edema without known risk factors.

    Kim MY, Alkhabaz A, Smith SJ, Liao YJ

    American journal of ophthalmology case reports 2024; (36()):102124 doi:10.1016/j.ajoc.2024.102124.

    PMID: 39156909
  22. 22

    Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.

    Jordan AL, Yang J, Fisher CJ, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2022; (28(1)):7-15 doi:10.1177/1352458520949158.

    PMID: 32808554
  23. 23

    72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.

    Ochi H, Niino M, Onizuka Y, et al.

    Advances in therapy 2018; (35(10)):1598-1611 doi:10.1007/s12325-018-0788-8.

    PMID: 30206820
  24. 24

    Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.

    Berger B, Baumgartner A, Rauer S, et al.

    Journal of neuroimmunology 2015; (282()):118-22.

    PMID: 25903738

This page is for informational purposes only and does not constitute medical advice. Your MS prescriber should interpret your test results and decide how to monitor or change treatment.

Guide contents relapsing-remitting multiple sclerosis
Research & Literature
03 Strategies for Control 05 Navigating Flares and Daily Symptoms